Use of Novel Combination Therapies in the Treatment of Advanced HR+/HER2-Breast Cancer

被引：3
作者：
Chang, Jenny C. [1 ]
O'Regan, Ruth [2 ,3 ,4 ]
机构：
[1] Houston Methodist Canc Ctr, Houston, TX 77030 USA
[2] Univ Wisconsin, Sch Med & Publ Hlth, Med, Madison, WI 53706 USA
[3] Carbone Canc Ctr, Hematololgy Oncol Div, Madison, WI USA
[4] Carbone Canc Ctr, Clin Res, Madison, WI USA
来源：
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2018年 / 16卷
关键词：
METASTATIC BREAST-CANCER; 4/6 INHIBITOR PALBOCICLIB; RANDOMIZED PHASE-II; FULVESTRANT; 500; MG; ANASTROZOLE; ENDOCRINE THERAPY; DOUBLE-BLIND; AROMATASE INHIBITORS; ESR1; MUTATIONS; 1ST-LINE TREATMENT;
D O I：
10.6004/jnccn.2018.0200
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Endocrine therapy remains the backbone for treatment of hormone receptor-positive breast cancer in the metastatic setting. Despite the effectiveness of endocrine therapy, primary and acquired endocrine resistance continue to be important clinical challenges. The landscape of metastatic breast cancer treatment has changed considerably with the incorporation of novel agents, including cyclin-dependent kinase 4/6 and mammalian target of rapamycin inhibitors. This article reviews current endocrine treatment strategies and recent and ongoing studies of combination therapies in metastatic hormone receptor-positive, HER2-negative breast cancer.
引用
收藏
页码：S1 / S14
页数：14
相关论文
共 76 条
[1]   Prognostic relevance of gene amplifications and coamplifications in breast cancer [J].
Al-Kuraya, K ;
Schraml, P ;
Torhorst, J ;
Tapia, C ;
Zaharieva, B ;
Novotny, H ;
Spichtin, H ;
Maurer, R ;
Mirlacher, M ;
Köchli, O ;
Zuber, M ;
Dieterich, H ;
Mross, F ;
Wilber, K ;
Simon, R ;
Sauter, G .
CANCER RESEARCH, 2004, 64 (23) :8534-8540
[2]   High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor-Positive Metastatic Breast Cancer [J].
Alves, Carla L. ;
Elias, Daniel ;
Lyng, Maria ;
Bak, Martin ;
Kirkegaard, Tove ;
Lykkesfeldt, Anne E. ;
Ditzel, Henrik J. .
CLINICAL CANCER RESEARCH, 2016, 22 (22) :5514-5526
[3]   Estrogen receptor alpha phosphorylation and its functional impact in human breast cancer [J].
Anbalagan, Muralidharan ;
Rowan, Brian G. .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2015, 418 :264-272
[4]  
[Anonymous], 2018, J CLIN ONCOL S
[5]  
[Anonymous], CANC RES S
[6]  
[Anonymous], 33 ANN MIAM BREAST C
[7]   Cyclin D1 in breast cancer pathogenesis [J].
Arnold, A ;
Papanikolaou, A .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (18) :4215-4224
[8]   Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study [J].
Bachelot, Thomas ;
Bourgier, Celine ;
Cropet, Claire ;
Ray-Coquard, Isabelle ;
Ferrero, Jean-Marc ;
Freyer, Gilles ;
Abadie-Lacourtoisie, Sophie ;
Eymard, Jean-Christophe ;
Debled, Marc ;
Spaeth, Dominique ;
Legouffe, Eric ;
Allouache, Djelila ;
El Kouri, Claude ;
Pujade-Lauraine, Eric .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (22) :2718-2724
[9]   Triplet therapy with ribociclib, everolimus, and exemestane in women with HR+/HER2-advanced breast cancer [J].
Bardia, A. ;
Modi, S. ;
Oliveira, M. ;
Campone, M. ;
Ma, B. ;
Dirix, L. ;
Weise, A. ;
Nardi, L. ;
Zhang, V. ;
Bhansali, S. G. ;
Hewes, B. ;
Chavez-MacGregor, M. .
CANCER RESEARCH, 2016, 76
[10]   SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA-mutant tumors [J].
Baselga, Jose ;
Cortes, Javier ;
DeLaurentils, Michelino ;
Dent, Susan ;
Dieras, Veronique ;
Harbeck, Nadia ;
Hsu, Jerry Y. ;
Jin, Huan ;
Schimmoller, Frauke ;
Wilson, Timothy R. ;
Im, Young-Hyuck ;
Jacot, William ;
Krop, Ian E. ;
Verma, Sunil .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345678